Search Results - "Poolman, J"

Refine Results
  1. 1
  2. 2
  3. 3

    O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands by Verboom, D.M., Varkila, M.R.J., Morrow, B., Davies, T., Ibarra de Palacios, P., Poolman, J., Hermans, P.W.M., Dudley, E.G., Roberts, E., Cremer, O.L., Bonten, M.J.M.

    Published in Vaccine (19-03-2021)
    “…•The burden of invasive ExPEC infections is increasing.•A glycoconjugate vaccine, containing ten E. coli O-antigens, is in development.•Vaccine effectiveness…”
    Get full text
    Journal Article
  4. 4

    A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children by Knuf, M, Kieninger-Baum, D, Habermehl, P, Muttonen, P, Maurer, H, Vink, P, Poolman, J, Boutriau, D

    Published in Vaccine (08-01-2010)
    “…Abstract Meningococcal disease incidence is highest in young children, yet a tetravalent conjugate vaccine is currently not available for this age group. This…”
    Get full text
    Journal Article
  5. 5

    Prediction of Pneumococcal Conjugate Vaccine Effectiveness against Invasive Pneumococcal Disease Using Opsonophagocytic Activity and Antibody Concentrations Determined by Enzyme-Linked Immunosorbent Assay with 22F Adsorption by Schuerman, L, Wysocki, J, Tejedor, J C, Knuf, M, Kim, K-H, Poolman, J

    Published in Clinical and Vaccine Immunology (01-12-2011)
    “…Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study by Leendertse, Anne J., MSc, Van Den Bemt, Patricia M.L.A., PhD, Poolman, J. Bart, BSc, Stoker, Lennart J., PharmD, Egberts, Antoine C.G., PhD, Postma, Maarten J., PhD

    Published in Value in health (2011)
    “…Abstract Objective Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Antigen-Specific Responses to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Human Infants Are Initially Th2 Polarized by ROWE, J, MACAUBAS, C, MONGER, T. M, HOLT, B. J, HARVEY, J, POOLMAN, J. T, SLY, P. D, HOLT, P. G

    Published in Infection and Immunity (01-07-2000)
    “…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  11. 11

    Protection against Streptococcus pneumoniae Elicited by Immunization with Pneumolysin and CbpA by OGUNNIYI, Abiodun David, WOODROW, Matthew C, POOLMAN, Jan T, PATON, James C

    Published in Infection and Immunity (01-10-2001)
    “…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  12. 12

    Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB by Pettersson, Annika, Kortekaas, Jeroen, Weynants, Vincent E., Voet, Pierre, Poolman, Jan T., Bos, Martine P., Tommassen, Jan

    Published in Vaccine (24-04-2006)
    “…The vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB was evaluated. Sequencing and sequence alignments suggested that…”
    Get full text
    Journal Article
  13. 13

    Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly by Örtqvist, Å, Henckaerts, I, Hedlund, J, Poolman, J

    Published in Vaccine (22-03-2007)
    “…Abstract During a randomised controlled trial with the 23-valent pneumococcal vaccine in older persons, antibody concentrations and opsonophagocytic activity…”
    Get full text
    Journal Article Conference Proceeding
  14. 14

    Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae by ALEXANDER, J. E, LOCK, R. A, PEETERS, C. C. A. M, POOLMAN, J. T, ANDREW, P. W, MITCHELL, T. J, HANSMAN, D, PATON, J. C

    Published in Infection and Immunity (01-12-1994)
    “…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  15. 15

    The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis by Jennings, Michael P, Srikhanta, Yogitha N, Moxon, E. Richard, Kramer, Marco, Poolman, Jan T, Kuipers, Betsy, van der Ley, Peter

    “…Department of Microbiology and Parasitology, The University of Queensland, Brisbane, QLD 4072, Australia 1 University of Oxford, Department of Paediatrics,…”
    Get full text
    Journal Article
  16. 16

    Enhancement of vaccine-specific cellular immunity in infants by passively acquired maternal antibody by Rowe, J., Poolman, J.T., Macaubas, C., Sly, P.D., Loh, R., Holt, P.G.

    Published in Vaccine (28-09-2004)
    “…The known protective effects of passively acquired maternal antibody on the resistance of newborns to infections have prompted widespread interest in maternal…”
    Get full text
    Journal Article
  17. 17

    Topology of outer membrane porins in pathogenic Neisseria spp by VAN DER LEY, P, HECKELS, J. E, HOOGERHOUT, P, POOLMAN, J. T

    Published in Infection and Immunity (01-09-1991)
    “…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  18. 18

    Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine by Peeters, C.C.A.M., Rümke, H.C., Sundermann, L.C., Rouppe van der Voort, E.M., Meulenbelt, J., Schuller, M., Kuipers, A.J., van der Ley, P., Poolman, J.T.

    Published in Vaccine (01-07-1996)
    “…A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer…”
    Get full text
    Journal Article
  19. 19

    Meningococcal lipopolysaccharides : virulence factor and potential vaccine component by VERHEUL, A. F. M, SNIPPE, H, POOLMAN, J. T

    Published in Microbiological reviews (01-03-1993)
    “…Lipopolysaccharides (LPS) are surface components of the outer membrane of Neisseria meningitidis. Today, 12 different types of meningococcal LPS (immunotypes)…”
    Get full text
    Journal Article
  20. 20